Clinical Trial Update: BC008-1A Injection for Recurrent CNS WHO G4 Glioma [Phase 1]

View source ↗

Summary

A Phase 1 study of BC008-1A Injection for recurrent central nervous system WHO Grade 4 glioma (including glioblastoma) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma
• High-grade Glioma

Drugs mentioned

• BC008-1A Injection (BC008-1A)

Snippet

Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Conditions: Glioma, Glioma Tumor Recurrence | Phase 1 | Status: RECRUITING